Veerhealth Care Ramps Up US Exports with 4–5 Monthly Shipments Post USFDA Clearance

Image Source: The Hindu Business Line

Veerhealth Care Ltd has commenced regular exports to the United States following USFDA approval for its OTC product line. The company has executed three full-container-load (FCL) shipments and now targets dispatching four to five shipments monthly, marking a strategic leap into regulated international markets.

Key Highlights:

The USFDA approval was granted on May 16, 2025, enabling commercial execution of orders for registered OTC products.
Initial shipments have been successfully delivered, and new orders from the same institutional US client are driving the monthly dispatch plan.
The company expects this development to significantly boost its revenue and strengthen its presence in the US healthcare segment.

Operational Expansion:

Veerhealth Care is renovating its Vapi, Gujarat facility to meet CGMP norms, with operations expected to begin in October 2024.
The upgraded plant will support increased production capacity for oral care and Ayurvedic products tailored for export markets.
The company is focused on timely execution of remaining orders and maintaining compliance with international quality standards.

Market Outlook:

Analysts anticipate a positive impact on quarterly earnings, with repeat orders contributing to a projected ₹18 crore annual run rate from the US client.
The company’s shares were trading flat at ₹23.98 on BSE, with potential upside as export volumes scale and regulatory credibility strengthens.

Sources: BSE Corporate Filings, The Hindu BusinessLine, Rediff MoneyWiz, Economic Times (July 2025)